Evidence map›Paper›PMID 39407305›Full record

ArticleJournal of ovarian research2024

Nur77 ameliorates cyclophosphamide-induced ovarian insufficiency in mice by inhibiting oxidative damage and cell senescence.

Ying Yao, Bin Wang, Kaihua Yu, Ji Song, Liyan Wang, Xia Yang, Xuehong Zhang, Yulan Li, Xiaoling Ma

Abstract read
In one paragraph

Article in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Protective effects ofFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying Yao *The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Bin Wang *Reproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.
Kaihua YuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
Ji SongReproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.
Liyan WangReproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.
Xia YangReproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.
Xuehong ZhangReproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China.
Yulan LiDepartment of Anesthesiology, The First Hospital of Lanzhou University, Lanzhou, China. liyul@lzu.edu.cn.
Xiaoling MaReproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, China. maxl2005@163.com.

Funding

Fund of the First Hospital of Lanzhou University ldyyyn2022-29Gansu Provincial Department of Education Project 2022B-015Natural Science Foundation of Gansu Province Project 23JRRA1617
6 · The paper itself

Abstract

Premature ovarian failure (POF) is among the primary causes of ovarian dysfunction that severely affects women's physical and mental health. The main purpose of this study was to explore the expression level of Nerve growth factor-induced protein B (Nur77/NR4A1) in cyclophosphamide (CTX)-induced POF. We then tested whether Nur77 can exert a protective effect after CTX treatment and investigated the mechanism of Nur77's role during ovarian injury. CTX promotes follicular atresia by inducing redox imbalance, apoptosis, and senescence, thereby causing direct toxicity to gonads. Additionally, CTX decreases ovarian reserve consumption by stimulating the excessive activation of primordial follicles. Nur77 can be stimulated by oxidative stress, DNA damage, metabolism, inflammation, etc. However, its relationship with POF remains unelucidated. We here found that Nur77 is expressed at low levels in POF ovaries. Therefore, Nur77 was identified as a regulator of ovarian injury and follicular development. According to the results, Nur77 overexpression alleviated redox imbalances, reduced cell senescence and apoptosis, and improved follicular reserve. Nur77 protects ovarian function by restoring disordered sex hormone levels and estrus cycles and promoting follicle growth and development at all levels. Moreover, the rapamycin protein kinase (AKT)/mammalian target of the rapamycin (mTOR) is a crucial regulator of the primordial follicle pool and follicular development. A relationship was observed between Nur77 and AKT through string and molecular docking. Experiments confirmed the involvement of the AKT/mTOR signaling pathway in the regulatory role of Nur77 in ovarian function. Thus, Nur77 is a critical target for POF prevention and treatment.

Indexed as

Cellular SenescenceCyclophosphamideNuclear Receptor Subfamily 4, Group A, Member 1Oxidative StressPrimary Ovarian InsufficiencyAnimalsApoptosisFemaleMiceOvarySignal TransductionTOR Serine-Threonine KinasesCyclophosphamideNr4a1 protein, mouseNuclear Receptor Subfamily 4, Group A, Member 1TOR Serine-Threonine KinasesAgingApoptosisCTXGranulosa cellsNur77POF

Identifiers

PMID39407305
PMCPMC11476119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.